CAMBRIDGE, Mass., Nov. 10, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today reported financial results and provided a business update for the third quarter ended September 30, 2016.
"During the third quarter of 2016, we made significant progress on our pipeline and were pleased to announce our newest drug discovery program for the treatment of fibrolamellar carcinoma, a rare liver cancer with a recognized genomic driver. This program highlights how quickly our science is moving to identify new and promising kinase drug targets, and our continued commitment to patients who need new treatment options," said Jeff Albers, Chief Executive Officer of Blueprint Medicines. "We believe the breadth of our pipeline is unique for a company of our size, and we are looking forward to announcing the early stage data on our three Phase 1 clinical trials before year-end."
"During the third quarter of 2016, we made significant progress on our pipeline and were pleased to announce our newest drug discovery program for the treatment of fibrolamellar carcinoma, a rare liver cancer with a recognized genomic driver. This program highlights how quickly our science is moving to identify new and promising kinase drug targets, and our continued commitment to patients who need new treatment options," said Jeff Albers, Chief Executive Officer of Blueprint Medicines. "We believe the breadth of our pipeline is unique for a company of our size, and we are looking forward to announcing the early stage data on our three Phase 1 clinical trials before year-end."
